Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.56 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.52 |
| ▸ | BCHE known ✓ | P06276 | 2/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.50 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.50 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14578048 | 0.99 | USP2 (0.60) | USP2SIGMAR1KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL5352820 | 0.91 | ALDH1A1 (0.60) | USP2SIGMAR1KMT2AALDH1A1KDM4E | |
| SCHEMBL5365088 | 0.88 | SIGMAR1 (0.69) | SIGMAR1KMT2AALDH1A1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL5353850 | 0.83 | ALDH1A1 (0.52) | SIGMAR1KMT2AALDH1A1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL3844581 | 0.83 | ALDH1A1 (0.69) | SIGMAR1KMT2AALDH1A1ACHEBCHE | |
| SCHEMBL5373264 | 0.81 | ALDH1A1 (0.67) | KMT2AALDH1A1ACHEBCHECYP3A4 | |
| SCHEMBL4512612 | 0.81 | ALDH1A1 (0.71) | SIGMAR1KMT2AALDH1A1ACHEBCHE | |
| Hydrochloric Acid SCHEMBL5358851 | 0.80 | HTR1A (0.66) | KMT2AALDH1A1HTTACHEBCHE | |
| Hydrochloric Acid SCHEMBL7293384 | 0.80 | HTR1A (0.66) | KMT2AALDH1A1HTTACHEBCHE | |
| Hydrochloric Acid SCHEMBL5354901 | 0.79 | CYP2D6 (0.58) | KMT2AALDH1A1LMNAACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2003-12-25 | — | — | US | claimed |
| US-6306857-B1 | INHIBITION OF ABNORMALLY PHOSPHORYLATED | MOLECULAR GERIATRICS CORPORATION | 2001-10-23 | — | — | US | claimed |
| WO-1996015792-A1 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| US-7173132-B2 | Certain substituted 1-aryl-3-piperazine-1′-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2003-12-25 | — | — | US | disclosed |
| US-6306857-B1 | INHIBITION OF ABNORMALLY PHOSPHORYLATED | MOLECULAR GERIATRICS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATARICS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6214994-B1 | TREATMENT OF NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS, AND PREVENTING OR DECREASING PRODUCTION OF PHOSPHORYLATED PAIRED HELICAL FILAMENT (PHF) EPITOPES ASSOCIATED WITH ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION | 2001-04-10 | — | — | US | disclosed |
| US-6075026-A | Certain substituted 1-aryl-3-piperazin-1'-yl propanones | MOLECULAR GERIATRICS, CORP. (US) | 2000-06-13 | — | — | US | disclosed |
| US-5693804-A | USEFUL IN TREATING NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS AND ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0792269-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5658909-A | INHIBITION OF ABNORMALLY PHOSPHORYLATED PAIRED HELICAL FILAMENT EPITOPE FORMATION | MOLECULAR GERIATRICS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996016052-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015792-A1 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | SIGMAR1 3020/4885GAA 3790/4885ACHE 3965/4885 |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | SIGMAR1 3020/4885GAA 3790/4885ACHE 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.